Post-Approval Safety of Cladribine Tablets with Particular Reference to COVID-19 Outcomes: An Update

Giovannoni G, et al. 

Long-term Efficacy for Patients Receiving Cladribine Tablets in CLARITY/CLARITY Extension: Primary Results from 9–15 Years of Follow-up in the CLASSIC-MS Study

Giovannoni G, et al. 

Real-world Experience with Cladribine in the MSBase Registry

Butzkueven H, et al. 

Cladribine Tablets after Treatment with Natalizumab (CLADRINA) Trial – Interim Analyses

Sguigna P, et al. 

MASTER-2 Trial: Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis or Active Secondary Progressive Multiple Sclerosis after Suboptimal Response to Prior Infusion/Oral Disease-Modifying Therapy (Interim Baseline Results)

Fox EJ, et al.

A Multi-Country Cohort Database Study to Assess Pregnancy and Infant Outcomes in Women Exposed to Cladribine Tablets: CLEAR Study

Hellwig K, et al. 

Improvements in QoL at 1 Year in Patients Treated with Cladribine Tablets for Highly Active Relapsing MS: An Interim Analysis of CLARIFY-MS

Solari A, et al. 

Incidence of Infections and Severe Lymphopenia in Patients Newly Initiating Cladribine Tablets or Fingolimod for Treatment of Multiple Sclerosis: CLARION Study

Hillert J, et al.

Disease-Modifying Treatment Patterns of Patients With Multiple Sclerosis and Newly Treated With Cladribine Tablets or Fingolimod: An Interim Analysis of the CLARION Study

Butzkueven H, et al.

High Adherence to Treatment with Cladribine Tablets for Multiple Sclerosis During the COVID-19 Pandemic: Results From Patient Support Programmes

Oh J, et al. 

Interferon Beta Exposure in the 2nd and 3rd Trimester of Pregnancy - A Register-Based Drug Utilisation Study in Finland and Sweden

Sabido M, et al. 

Exploratory Analysis of Serum GDF-15 Levels in Patients Receiving Subcutaneous Interferon β-1a in the REFLEX Trial

Coray M, et al. 

Development and Interrelation of Spatiotemporal Patterns of Brain Atrophy and Lesions During 5 Years’ Treatment with Subcutaneous Interferon Beta-1a in Patients with a First Clinical Demyelinating Event in the REFLEX/ION Study

Gentile G, et al. 

Development and Interrelation of Whole-Brain Atrophy and Lesion Volume During 5 Years’ Treatment with Subcutaneous Interferon Beta-1a in Patients with a First Clinical Demyelinating Event in the REFLEX/ION Study

Mattiesing RM, et al. 

Genome-Wide Mapping of Patient Autoantibody Targets to Understand and Predict Multiple Sclerosis Pathogenesis and Patient Responses to Interferon Beta-1a Therapy

DiCillo EB, et al.

Safety Profile Characterization of Evobrutinib in Over 1000 Patients from Phase II Clinical Trials in Multiple Sclerosis, Rheumatoid Arthritis and Systemic Lupus Erythematosus

Montalban X, et al. 

The Role of Human and Mouse BTK in Myeloid Cells

Bassani C, et al.

Targeting BTK in Chronic CNS Autoimmunity Inhibits Activation of Microglia

Geladaris A, et al. 

Evobrutinib Significantly Reduces Relapses and Magnetic Resonance Imaging Outcomes in Patients with Multiple Sclerosis: Association with Baseline Neurofilament Light Chain Levels

Kuhle J, et al. 

Effects of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor, on Slowly Expanding Lesions: An Emerging Imaging Marker of Chronic Tissue Loss in Multiple Sclerosis

Arnold D, et al. 

Towards a New Resource for the MS Brain: A Cross Brain Bank Proteomic Atlas of Non Lesional Neocortex

Bouman P, et al.

DISCOntinuation of Disease Modifying therapies in MS (DISCOMS) Extension Study Design and Baseline Demographics

Engebretson E, et al. 

Risk of Cancer with Disease-Modifying Therapies in Multiple Sclerosis: A New-User Cohort Design in the French Nationwide Claims Database

Bosco-Levy P, et al.